Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Jun 10–Jun 17, 2026)

· 1 min read

This week brings a focused slate of clinical readouts, with Osteoxenon (OSTX) commanding attention through two distinct oncology programs. The most intriguing catalyst may be OSTX’s CD33 CAR-T data in relapsed AML, as the competitive cellular therapy landscape continues evolving. SignalPoint’s exercise physiology study rounds out a lighter-than-usual catalyst calendar.

🧪 Trial Catalysts & Milestones

  • SIGN — 2026-06-10: Running Environment and Psychophysiological Responses
  • OSTX — 2026-06-15: Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Tre
  • OSTX — 2026-06-15: Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia

📡 Run-up Radar Highlights

Stocks entering the pre-catalyst window with the strongest setups (full radar is a Premium feature):

  • UNCY — NDA in 19 days, score 78/100
  • ADCT — Phase 3 — Active Trial in 20 days, score 57/100
  • IBRX — Phase 2 — Recruiting in 21 days, score 55/100

📈 Last Week’s Biggest Gainers

  • TNGX +52.97% (volume 6.5x average)
  • NUVL +39.28% (volume 77.0x average)
  • ALHC +25.08% (volume 3.4x average)
  • CHRN +22.69% (volume 3.3x average)
  • FRMI +22.60% (volume 3.5x average)

Track your tickers on the BioRadar dashboard →

This digest is for informational purposes only and is not investment advice. Always do your own research.

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.